Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Treatment With LP352 for Patients With Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)

Next Previous
Trial Profile

Expanded Access Treatment With LP352 for Patients With Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexicaserin (Primary)
  • Indications Epilepsy
  • Focus Expanded access; Therapeutic Use
  • Sponsors Longboard Pharmaceuticals

Most Recent Events

  • 02 Dec 2024 According to a Lundbeck A/S media release, the company has acquired Longboard Pharmaceuticals and it is now a wholly owned subsidiary of Lundbeck.
  • 30 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top